Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 08:30 AM ET – Continuing Jobless Claims

✓ 01:00 PM ET – 30-Year Bond Auction

✓ 02:00 PM ET – FOMC Member Daly Speaks

✓ 04:30 PM ET – Fed's Balance Sheet

PREMARKET SNAPSHOT 📈

Stock Futures: Dow Jones surges 0.44%, S&P 500 and NASDAQ see flat movement pre-market.

SECTOR SNAPSHOT ✨

Most volatile sector today: Utilities (up 1.05%) followed by Real Estate (down 0.9%).

Unusual Volume

📈 Fuelcell Energy Inc (FCEL) declined -3.52% to $0.76 on a whopping 84.33 million shares traded.

📈 Investors went wild, sending Uber Technologies Inc (UBER) stock declining -5.72% to $66.40 on a massive volume of 83.94 million shares after the company released results for first quarter 2024.

📈 Abnormal activity shook Safe and Green Development Corp (SGD), pushing it up 58.81% to $0.62 on a whopping 69.6 million shares traded after announcing that it has entered into an agreement to acquire MyVONIA.

📈 Luminar Technologies Inc (LAZR) stock recently closed 18.79% upper at $1.96 on substantial volume of 60.67 million shares. This unusual activity came after the company reported first quarter 2024 business update and financials.

📈 Shopify Inc (SHOP) decrease by -18.59% in a single trading session, with abnormally high trading volume of 58.13 million shares following the release of its Q1 2024 financial results.

Premarket Movers

Greenwave Technology Solutions, Inc. (GWAV) experiences a substantial 28.74% surge in pre-market trading after announcing that its Chairman and Chief Executive Officer, has exchanged an aggregate of approximately $17.22 million in debt into equity comprised of (i) $10.00 million in debt exchanged for shares of Series D Preferred Stock and (ii) $7.22 million in debt exchanged into common stock at $0.1167 per share.

Pop Culture Group Co., Ltd (CPOP) sees a significant 85.20% increase, reaching a pre-market price of $3.13 after reporting strong performance for the first half of 2023.

X4 Pharmaceuticals, Inc. (XFOR) demonstrates a noteworthy 12.50% surge, with a pre-market price of $1.20. The company announced $125 million capital infusion from $105 million sale of priority review voucher and $20 million drawdown from Existing Loan Facility.

Important FDA 

Recently Announced

April 29th, 2024, marks a significant milestone for Pfizer Inc. With the FDA's decision to grant full approval for TIVDAK, Pfizer achieves a crucial breakthrough in the treatment landscape for patients battling recurrent or metastatic cervical cancer. This decision underscores the efficacy and safety of Tivdak, offering renewed hope and potential for improved outcomes in a patient population facing challenging prognoses post-initial therapy.

On April 30th, 2024, Neurocrine Biosciences Inc. (NBIX) celebrates a monumental achievement with the FDA's approval of INGREZZA's oral granules formulation. This innovative development in drug delivery heralds a new era in the management of tardive dyskinesia and chorea associated with Huntington's disease.

Amidst recent announcements, April 30th, 2024, stands out as a historic day for X4 Pharmaceuticals, Inc (XFOR). The FDA's approval of Mavorixafor offers a ray of hope to individuals aged 12 and older afflicted with WHIM syndrome. This decision not only validates the efficacy and safety of Mavorixafor but also signifies a critical advancement in the treatment landscape for a rare and challenging condition.

Upcoming Announcements

Moderna, Inc. (MRNA): Excitement surges in anticipation of Moderna's pivotal moment on May 12th, 2024. As the countdown to the FDA decision for mRNA-1345, their groundbreaking RSV vaccine, draws near, stakeholders hold their breath. Should the verdict align with expectations, it could mark a significant leap forward in combating respiratory syncytial virus, promising a safer and more effective means of protection against this pervasive threat.

Dynavax Technologies Corp. (DVAX): May 13th, 2024, marks a crucial juncture for Dynavax Technologies Corp. The company awaits the FDA's verdict on HEPLISAV-B, a vaccination with the potential for expanded use in adults undergoing hemodialysis. As the date approaches, anticipation builds among stakeholders, poised on the brink of a potential breakthrough that could enhance the standard of care for this vulnerable patient population.

Ascendis Pharma A/S (ASND): On May 14th, 2024, all eyes turn to Ascendis Pharma A/S as they await the FDA decision on TransCon PTH. With the resubmitted NDA aiming to address the pressing needs of adult patients grappling with hypoparathyroidism, the outcome holds profound implications. Should the verdict be favorable, it could herald a new era of treatment options, offering hope and relief to those burdened by this challenging condition.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.